ADMA Biologics/$ADMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
- Ticker
- $ADMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 644
- Headquarters
- Ramsey, United States
- Website
- www.admabiologics.com
ADMA Biologics Metrics
BasicAdvanced
$2.2bn
13.96
$0.70
-
-
Price and volume
Market cap
$2.2bn
52-week high
$20.46
52-week low
$7.21
Average daily volume
2.7m
Financial strength
Current ratio
6.972
Quick ratio
3.62
Long term debt to equity
48.728
Total debt to equity
49.935
Interest coverage (TTM)
24.53%
Profitability
EBITDA (TTM)
224.193
Gross margin (TTM)
64.71%
Net profit margin (TTM)
32.98%
Operating margin (TTM)
42.26%
Effective tax rate (TTM)
21.95%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
21.78%
Return on equity (TTM)
41.90%
Valuation
Price to earnings (TTM)
13.964
Price to revenue (TTM)
4.491
Price to book
5.4
Price to tangible book (TTM)
5.45
Price to free cash flow (TTM)
19.793
Free cash flow yield (TTM)
5.05%
Free cash flow per share (TTM)
0.494
Growth
Revenue change (TTM)
8.04%
Earnings per share change (TTM)
-17.00%
3-year revenue growth (CAGR)
35.02%
10-year revenue growth (CAGR)
50.21%
3-year earnings per share growth (CAGR)
54.21%
10-year earnings per share growth (CAGR)
-9.26%
What the Analysts think about ADMA Biologics
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
ADMA Biologics Financial Performance
Revenues and expenses
ADMA Biologics Earnings Performance
Company profitability
ADMA Biologics News
AllArticlesVideos
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Newsfile Corp1 day ago
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Business Wire3 days ago
ADMA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Newsfile Corp4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.